Our experienced IP attorneys and IP lawyers regularly contribute to the IP publications produced by Griffith Hack. Our publications cover a range of IP issues in Australia and overseas, in such areas as patents, trade marks, copyright, designs, IP legal issues, trade practices, legislative updates, and the management of IP. We also bring you interesting news, events and insights about Griffith Hack and our clients.

Breakthrough - is a quarterly newsletter produced in printed and electronic format that provides a variety of news and information on IP in Australia and overseas, together with interesting features on our firm, our clients and any upcoming events.

Need-to-Know - is a newsletter produced in electronic format to update clients on the latest issues and legal developments within the IP industry.

If you would like to subscribe to our newsletters, please click click here.

Breakthrough Newsletter

Issue 4 2009 (PDF 0.78Mb)
Feature articles this month include:

• A recent decision in the case of Chocolaterie Guylian N.V. v Registrar of Trade Marks [2009] FCA 891 provides guidance on whether a shape mark is inherently capable of distinguishing an applicant’s goods and, if not, what evidence is required to show that the trade mark has become capable of distinguishing through use.
• As a recent case demonstrates, the ‘grace period’ for divisional patent applications is activated by the filing date of the parent application.
• Generic companies seeking to market generic pharmaceutical products must have their ‘eyes wide open’ to the risk of interlocutory injunctions and actively monitor the patent position of the intended product.
• Keeping a close eye on their intellectual property (IP) helps this Australian biotech company stay one step ahead of the pack.
• Griffith Hack was the proud gold sponsor of the recent 2009 Curtin Commercial Innovation Awards.

To view newsletter archive, please click here.

Need-to-know Newsletter

Interlocutory injunction granted in a pharmaceutical patent infringement case (Nov 2008)
The latest pharmaceutical patents to come under attack in court in Australia are two patents for Lilly’s Gemzar oncology drug. The active agent in Gemzar is gemcitabine hydrochloride. Gemzar is protected, in Australia, by two patents – one for the compound (the compound patent) and one for a process relating to the manufacture of gemcitabine hydrochloride (the process patent).

To view newsletter archive, please click here.